Sign in
Taking peoplePhase 3

Baricitinib compared with placebo for polymyalgia rheumatica

Tests baricitinib with short steroid treatment in adults with polymyalgia rheumatica.

Key facts

Who runs it
Centre Hospitalier Regional Et Universitaire De Brest
Where
France22 sites in 1 countryChoose a country to see its sites
Registry title
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
Status
Recruiting
Phase
Phase 3
People taking part
140 people, planned
Started
18 Dec 2025
Expected to end
1 Jun 2028
Type of study
Interventional
Record updated
19 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 or older with polymyalgia rheumatica (PMR), newly diagnosed or not responding to treatment. It compares baricitinib with placebo, both given with a short course of steroids.

Age
At least 50 years old.
Sex
All sexes can join.
Disease stage
PMR that meets the ACR/EULAR classification criteria, either newly diagnosed or resistant to treatment. Disease activity score PMR-AS-CRP must be above 17. No other inflammatory joint disease, connective tissue disease or vasculitis (inflamed blood vessels).
Earlier treatment
For at least 15 days before the start, either no steroids (GCs) or steroids below 15 mg/day. People taking probenecid cannot join.
Biomarker or test result
PMR-AS-CRP score above 17.

Main reasons for not taking part

  • Signs of giant cell arteritis.
  • Cancer in the last 5 years (3 years for some removed skin or cervical cancers).
  • Active uncontrolled infection, or uncontrolled high blood pressure or heart disease.
  • Blood clot (VTE) within 12 weeks before the start, or more than 1 clot in the past.
  • Current smokers older than 65 years.

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • At least 50 years of age
  • Fulfilling ACR/EULAR classification criteria for PMR newly diagnosed or treatment resistant
  • No GCs or GCs <15 mg/day since at least 15 days prior to planned randomization
  • PMR-AS-CRP >17
  • Absence of other inflammatory arthropathy, connective tissue diseases or vasculitis
  • Able to give informed consent
  • French health insurance holder

Who cannot take part

  • High risk of VTE because of a history of VTE (DVT and/or PE) within 12 weeks prior to randomization or a history of recurrent (>1) VTE (counting co-occurring DVT+PE as 1 single event)
  • History of malignant neoplasm within the last 5 years (or 3 years in case of cervical carcinoma, basal cell or squamous epithelial skin cancer resected with no evidence of recurrence or metastatic disease)
  • Current active uncontrolled infection
  • Uncontrolled high blood pressure or cardiovascular disease
  • Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR
  • Planned major surgical procedure during the study or medical history, blood abnormalities or any clinical condition that compromises inclusion
  • Alkaline phosphatase (ALP) ≥2 x ULN
  • Total bilirubin level (TBL) ≥1.5 x ULN
  • Neutropenia (absolute neutrophil count <1000 cells/uL) (<1.00 x 103/uL or <1.00 GI/L)
  • Lymphopenia (lymphocyte count <500 cells/uL) (<0.50 x 103/uL or <0.50 GI/L)
  • Detailed exclusion criteria related to prior or concomitant therapy, general safety and laboratory data are reported in the protocol
  • Current smoker if age >65 years
  • Clinical evidence of giant cell arteritis
  • Treatment by probenecid
  • Patient under court protection or protected adults

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To demonstrate the ability of baricitinib 4 mg plus short GCs treatment in comparison to placebo plus short GCs treatment to obtain a disease activity [PMR-AS-CRP] lower or equal to 10 without oral GCs (prednisone or prednisolone) at week 24 in PMR patients.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study)
Plain-language title
Baricitinib compared with placebo for polymyalgia rheumaticaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Record updated
19 June 2026